Trial Profile
A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Micafungin (Primary) ; Amphotericin B
- Indications Candidaemia; Invasive candidiasis
- Focus Registrational; Therapeutic Use
- Acronyms MAGIC-2
- Sponsors Astellas Pharma
- 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
- 20 Jan 2015 Status changed from active, no longer recruiting to discontinued as reported in ClinicalTrials.gov record
- 24 Nov 2014 Planned End Date changed from 1 Dec 2016 to 1 Dec 2015 as reported in ClinicalTrials.gov record.